WHICH CLINICAL MEASURES ARE MOST APPROPRIATE FOR MEASURING DISEASE PROGRESSION IN PARKINSON'S DISEASE?. Issue 11 (9th October 2013)

• Record Type: Journal Article
• Authors: McGhee, David; Parker, Alexander; Fielding, Shona; Counsell, Carl
• Is Part Of: Journal of neurology, neurosurgery and psychiatry. Volume 84:Issue 11(2013)
• Page Start: e2
• Page End: e2
• Publication Date: 2013-10-09
• Subjects: PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE -- PARKINSON'S DISEASE -- STROKE; Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Psychiatry -- Periodicals; 616.8
• DOI: 10.1136/jnnp-2013-306573.163
• Languages: English
• ISSNs: 0022-3050

Abstract

Abstract : Objectives: To determine which clinical measures of disease progression in Parkinson's disease (PD) can feasibly be measured across the disease spectrum and which are most sensitive to change. Background: Understanding the feasibility of measuring clinical outcomes and their sensitivity to change is crucial when choosing outcome measures for trials of putative neuroprotective drugs in PD. Methods: People with clinically defined PD were identified from an on–going long–term follow–up study of incident parkinsonian patients. Annual follow–up included a motor UPDRS, MMSE, Schwab and England, and a timed–walk. In cases of advanced consent a full UPDRS, timed hand–taps, MMP, PDQ–39, EuroQol–5Dindex, EQ–VAS and the Barthel index were also completed. Using data from consenting patients who completed each annual follow–up, percentage completion of collection for each measure over five years was examined. In a subset that completed three years of follow–up, linear mixed modelling was used to determine if clinical measures changed significantly over time. Sensitivity to change was assessed by grouping the measures (motor impairment, disability, quality of life, and cognition) and comparing the percentage change in each from baseline. Results: Annual percentage completion of all measures (n=203 at baseline) was high (>80%) over five years. Change over time was examined in 176 patients who had completed three–years of follow–up. All measures, except the stigma (P=0.102) and social (P=0.177) subsections of the PDQ–39, demonstrated significant progression over three–years. The PDQ–39 summary index and its subsections were most sensitive to change (motor impairment, PDQ–39 mobility; disability, PDQ–39 ADL; quality of life, PDQ–39 summary index; cognition, PDQ–39 cognition). Conclusions: Collection of all examined clinical measures was feasible. The PDQ–39 summary index and subsections were most sensitive to change.